Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy
A Veeravagu, AR Hsu, W Cai, LC Hou… - Recent patents on …, 2007 - ingentaconnect.com
New blood vessel formation (angiogenesis) is fundamental to the process of tumor growth,
invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) …
invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) …
Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy
TL Underiner, B Ruggeri… - Current medicinal …, 2004 - ingentaconnect.com
Among the known angiogenic growth factors and cytokines implicated in the modulation of
normal and pathological angiogenesis, the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF …
normal and pathological angiogenesis, the VEGF family (VEGF-A, VEGF-B, VEGF-C, VEGF …
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway
JM Roodhart, MH Langenberg… - Current clinical …, 2008 - ingentaconnect.com
Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important
regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical …
regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical …
The VEGF/VEGFR axis revisited: implications for cancer therapy
P Mabeta, V Steenkamp - International journal of molecular sciences, 2022 - mdpi.com
The vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor
(VEGFR) axis is indispensable in the process of angiogenesis and has been implicated as a …
(VEGFR) axis is indispensable in the process of angiogenesis and has been implicated as a …
A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
Angiogenesis plays an important role in the formation of new blood vessels and is crucial for
tumour development and progression. Imbalance between pro-and antiangiogenesis factors …
tumour development and progression. Imbalance between pro-and antiangiogenesis factors …
Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor
Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …
human development and reproduction; however, aberrant regulation of angiogenesis is also …
Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis
AK Larsen, D Ouaret, K El Ouadrani… - Pharmacology & …, 2011 - Elsevier
The last decade has witnessed the approval of monoclonal antibodies (mAbs) and small
molecule tyrosine kinase inhibitors (TKIs) for targeting of oncogenic signaling pathways …
molecule tyrosine kinase inhibitors (TKIs) for targeting of oncogenic signaling pathways …
Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy
S Takahashi - Biological and Pharmaceutical Bulletin, 2011 - jstage.jst.go.jp
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have crucial roles in
both physiological and pathological angiogenesis. The VEGF family consists of VEGF-A …
both physiological and pathological angiogenesis. The VEGF family consists of VEGF-A …
Resistance mechanisms to anti-angiogenic therapies in cancer
Tumor growth and metastasis rely on tumor vascular network for the adequate supply of
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
E Bello, G Colella, V Scarlato, P Oliva, A Berndt… - Cancer research, 2011 - AACR
Tumor angiogenesis is a degenerate process regulated by a complex network of
proangiogenic factors. Existing antiangiogenic drugs used in clinic are characterized by …
proangiogenic factors. Existing antiangiogenic drugs used in clinic are characterized by …